Cyclic Peptide SVLPs for Adjuvant-Free RSV Prophylaxis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments and vaccines for respiratory syncytial virus (RSV) are limited by high costs, safety risks, and ineffective immunization, necessitating a need for a safer and more cost-effective prophylactic approach.
Innovation Solution
Development of cyclic peptides mimicking the Palivizumab antigenic peptide, coupled to synthetic virus-like particles (SVLPs), which induce neutralizing antibodies without adjuvants, stabilizing through disulfide bridges for effective RSV protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibody Palivizumab is used for RSV prophylaxis, then protective effect is achieved, but multiple doses are required due to short half-life increasing cost and inconvenience
Solution Approach 1:
The patent creates synthetic virus-like particles that copy the essential immunogenic features of RSV without using the actual virus. These SVLPs display RSV F protein epitopes (including the Palivizumab binding site) on their surface, mimicking the natural virus structure enough to elicit protective neutralizing antibodies, but in a simplified, safer, and more cost-effective manner that does not require multiple expensive monoclonal antibody doses
Solution Approach 2:
The patent modifies the physical and chemical parameters of the vaccine platform by using synthetic virus-like particles with specific structural characteristics (size, surface display of epitopes, stability) that optimize immunogenicity while reducing the need for repeated dosing. The SVLPs are designed to present antigens in a configuration that elicits strong, long-lasting immune responses
2Reliability
If RSV vaccine is developed to induce neutralizing antibodies, then protection against infection is achieved, but vaccine-associated enhanced respiratory disease (VAERD) may be activated
Solution Approach 1:
The patent extracts only the essential protective antigenic components (RSV F protein epitopes, particularly the Palivizumab binding site) from the complete virus structure. By displaying these specific neutralizing epitopes on synthetic virus-like particles without including other viral components that might trigger harmful immune responses, the vaccine elicits protective immunity while minimizing the risk of VAERD
Solution Approach 2:
The synthetic virus-like particles serve as an intermediary structure that presents RSV antigens to the immune system in a controlled, safe manner. These SVLPs mediate the interaction between the host immune system and RSV antigens, eliciting neutralizing antibodies without causing the enhanced disease associated with whole-virus or inactivated vaccine approaches
3Adaptability or versatility
If formalin inactivated vaccine is used for immunization, then immunization is achieved, but severely enhanced disease occurs due to imbalanced cell-mediated immune responses
Solution Approach 1:
The patent fundamentally changes the vaccine platform from chemically inactivated whole virus to synthetic virus-like particles with defined structural parameters. This parameter change in the vaccine architecture allows for controlled presentation of epitopes that direct the immune response toward protective neutralizing antibodies rather than harmful cell-mediated responses
Solution Approach 2:
The synthetic virus-like particles are composite structures combining synthetic components (such as self-assembling peptides or protein shells) with displayed RSV F protein epitopes. This composite approach creates a vaccine platform that elicits balanced immune responses, prioritizing humoral immunity with neutralizing antibodies while avoiding the imbalanced cell-mediated responses that cause enhanced disease
4Reliability
If cyclic peptides are used to mimic Palivizumab antigenic peptide, then neutralizing antibody induction is achieved, but peptide stability must be maintained without adjuvants
Solution Approach 1:
The patent creates composite cyclic peptide structures with disulfide bridges that combine the immunogenicity of peptide antigens with the structural stability of cross-linked cyclic frameworks. These disulfide-stabilized cyclic peptides resist proteolytic degradation and maintain their immunogenic conformation without requiring adjuvants, achieving both stability and neutralizing antibody induction
Solution Approach 2:
The patent performs preliminary structural stabilization of the peptide antigen by introducing disulfide bridges before immunization. This preliminary action of pre-organizing the peptide into a stable, immunogenic conformation ensures that the antigen maintains its structure during storage and administration, enabling effective neutralizing antibody induction without adjuvant support
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptides elicit potent neutralizing antibodies, providing broad protection against RSV without activating vaccine-associated enhanced respiratory disease (VAERD) and are cost-effective for a wider population.
Implementation Method 1
stabilizing through disulfide bridges for effective RSV protection
Data Source
AI summary
The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.